NASDAQ:CMPS Compass Pathways (CMPS) Stock Price, News & Analysis $11.25 -0.10 (-0.88%) Closing price 08/3/2026 04:00 PM EasternExtended Trading$11.44 +0.19 (+1.69%) As of 08/3/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Compass Pathways Stock (NASDAQ:CMPS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Compass Pathways alerts:Sign Up Key Stats Today's Range$11.02▼$11.5450-Day Range$10.85▼$15.0752-Week Range$3.97▼$15.40Volume2.77 million shsAverage Volume4.42 million shsMarket Capitalization$1.52 billionP/E RatioN/ADividend YieldN/APrice Target$23.36Consensus RatingModerate Buy Company Overview Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S. Food and Drug Administration. In addition to its lead depression program, Compass Pathways is exploring broader applications of psychedelic-assisted therapies in areas such as anorexia nervosa and other mood disorders. The company has built a scalable manufacturing process for synthetic psilocybin and established a network of trained therapists and research sites across Europe and North America. Compass also leverages digital tools to capture patient-reported outcomes and physiological data, supporting personalized treatment protocols and enhancing safety monitoring throughout clinical studies. Since its initial public offering in September 2020, Compass Pathways has advanced its pipeline through rigorous clinical partnerships and academic collaborations. The leadership team is led by co-founder and CEO George Goldsmith, who has guided the company through regulatory milestones and strategic alliances. With a board of directors comprising experts in neuroscience, clinical research, and life sciences commercialization, Compass remains committed to transforming the treatment paradigm for mental health by combining innovative science, patient-centered care, and robust regulatory engagement. AI Generated. May Contain Errors. Read More Compass Pathways Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreCMPS MarketRank™: Compass Pathways scored higher than 66% of companies evaluated by MarketBeat, and ranked 265th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCompass Pathways has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 14 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCompass Pathways has a consensus price target of $23.36, representing about 107.6% upside from its current price of $11.25.Amount of Analyst CoverageCompass Pathways has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Compass Pathways' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Compass Pathways are expected to decrease in the coming year, from ($1.24) to ($1.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compass Pathways is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compass Pathways is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Compass Pathways' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.79% of the float of Compass Pathways has been sold short.Short Interest Ratio / Days to CoverCompass Pathways has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Compass Pathways has recently increased by 26.24%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCompass Pathways does not currently pay a dividend.Dividend GrowthCompass Pathways does not have a long track record of dividend growth. News and Social Media4.5 / 5News Sentiment1.27 News SentimentCompass Pathways has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Compass Pathways this week, compared to 4 articles on an average week.Search Interest29 people have searched for CMPS on MarketBeat in the last 30 days. This is an increase of 263% compared to the previous 30 days.MarketBeat Follows16 people have added Compass Pathways to their MarketBeat watchlist in the last 30 days. This is an increase of 129% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Compass Pathways insiders have not sold or bought any company stock.Percentage Held by Insiders2.82% of the stock of Compass Pathways is held by insiders.Percentage Held by Institutions46.19% of the stock of Compass Pathways is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Compass Pathways' insider trading history. Receive CMPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compass Pathways and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMPS Stock News HeadlinesCompass Pathways (NASDAQ:CMPS) Earns Equal Weight Rating from Analysts at Wells Fargo & CompanyJuly 30, 2026 | americanbankingnews.comCompass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026July 29, 2026 | businesswire.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits. | Porter & Company (Ad)Compass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapyJuly 17, 2026 | proactiveinvestors.comATAI stock soars on Eli Lilly’s $2.8B buyout – why are CMPS shares rising too?July 16, 2026 | msn.comCompass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from PsychotherapyJuly 16, 2026 | businesswire.comCMPS stock climbs after-hours: Analyst sees depression drug approval by H1 2027 or sooner after strong trial dataJuly 9, 2026 | msn.comCompass Pathways upgraded at Evercore after latest data for psychedelic therapyJuly 8, 2026 | seekingalpha.comSee More Headlines CMPS Stock Analysis - Frequently Asked Questions How have CMPS shares performed this year? Compass Pathways' stock was trading at $6.90 on January 1st, 2026. Since then, CMPS stock has increased by 63.0% and is now trading at $11.25. How were Compass Pathways' earnings last quarter? Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) issued its earnings results on Wednesday, May, 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.15. Read the conference call transcript. When did Compass Pathways IPO? Compass Pathways (CMPS) raised $112 million in an IPO on Friday, September 18th 2020. The company issued 7,500,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Compass Pathways' major shareholders? Top institutional investors of Compass Pathways include Hennion & Walsh Asset Management Inc. (0.31%) and Stableford Capital II LLC (0.07%). Insiders that own company stock include Life Sciences NV Atai, Ekaterina Malievskaia and George Jay Goldsmith. View institutional ownership trends. How do I buy shares of Compass Pathways? Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Compass Pathways own? Based on aggregate information from My MarketBeat watchlists, some other companies that Compass Pathways investors own include Symbotic (SYM), Enovix (ENVX), Rambus (RMBS), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA). Company Calendar Last Earnings5/13/2026Today8/03/2026Next Earnings (Confirmed)8/05/2026Canaccord Genuity's 46th Annual Growth Conference8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 CMPS's financial health is in the Green zone, according to TradeSmith. CMPS has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CMPS CIK1816590 Webwww.compasspathways.com Phone716-676-6461FaxN/AEmployees120Year Founded2016Price Target and Rating Average Price Target for Compass Pathways$23.36 High Price Target$70.00 Low Price Target$13.00 Potential Upside/Downside+107.6%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($3.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$287.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-31.07% Return on Assets-11.40% Debt Debt-to-Equity Ratio0.15 Current Ratio3.32 Quick Ratio3.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.55) per share Price / Book-20.45Miscellaneous Outstanding Shares134,950,000Free Float131,143,000Market Cap$1.52 billion OptionableOptionable Beta2.50 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CMPS) was last updated on 8/4/2026 by MarketBeat.com Staff. From Our PartnersWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredThis AI fund sends investors payouts every ThursdayCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | Sponsored1 Stock to Own by July 31stA scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...Chaikin Analytics | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Pathways PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Pathways With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
